Participant flow

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms · Source last updated 2023-06-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \[max. 2 mg\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.

   id

   FG000

   title

   Treatment (A-CHOP Followed by MA)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Never started treatment

   2. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Patient ineligible

   3. reasons

      1. group Id

         FG000

         num Subjects

         13

      type

      Lack of Efficacy

   4. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Adverse Event

   5. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Withdrawal by Subject

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Other complicating disease

   7. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Other

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         46

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         44

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         39

      type

      Eligible and Treated

   4. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         37

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The first patient was accrued on September 14, 2006.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice